{"id":"NCT01877655","sponsor":"Astellas Pharma Global Development, Inc.","briefTitle":"A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-11","primaryCompletion":"2017-09-28","completion":"2022-03-01","firstPosted":"2013-06-14","resultsPosted":"2018-11-28","lastUpdate":"2024-10-24"},"enrollment":514,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Cytomegalovirus (CMV)-Positive Recipients","Allogeneic, Hematopoietic Cell Transplant (HCT)"],"interventions":[{"type":"BIOLOGICAL","name":"ASP0113","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"ASP0113","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant. Safety of ASP0113 in participants undergoing allogeneic HCT will also be evaluated.","primaryOutcome":{"measure":"Percentage of Participants With Composite of All-Cause Mortality and Adjudicated Cytomegalovirus End Organ Disease (CMV EOD) Through 1 Year Post Transplant","timeFrame":"From first study dose injection (Day -14 to -3 prior to transplant) up to one year post study drug injection (Day 365)","effectByArm":[{"arm":"Placebo","deltaMin":30.2,"sd":null},{"arm":"ASP0113","deltaMin":35.37,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.205"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":83,"countries":["United States","Australia","Belgium","Canada","France","Germany","Japan","South Korea","Spain","Sweden","Taiwan"]},"refs":{"pmids":["33842870"],"seeAlso":["https://www.clinicaltrials.astellas.com/study/0113-CL-1004/","https://ast.trialsummaries.com/Study/StudyDetails?id=14598&tenant=MT_AST_9011"]},"adverseEventsSummary":{"seriousAny":{"events":221,"n":255},"commonTop":["Nausea","Diarrhoea","Pyrexia","Vomiting","Injection site pain"]}}